Drug intelligence / Profile preview

IBI314-B

Development stage: Discontinued
Lead developer: Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI314-B is a potent SARS-CoV-2 neutralizing antibody developed by Innovent Biologics. It is one of two antibodies (IBI314A and IBI314B) that constitute the investigational drug IBI314. IBI314-B targets distinct and non-overlapping epitopes on the SARS-CoV-2 S protein, acting as an inhibitor to prevent viral entry and replication. The combination drug IBI314 was investigated for the treatment of COVID-19, demonstrating efficacy in reducing viral load and alleviating clinical symptoms in patients infected with Delta and Omicron variants, and was generally well-tolerated.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on IBI314-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI314-B.

Explore the full profile